外周血单核细胞亚群分析在慢性粒-单核细胞白血病中的应用
该单中心回顾性研究纳入51例初诊CMML患者和23例非CMML髓系肿瘤伴单核细胞增多患者,采用流式细胞术检测外周血单核细胞亚群。结果显示CMML患者MO1亚群比例显著高于对照组,MO1亚群分析可辅助CMML诊断,但需排除炎症状态。
要点
- CMML患者外周血MO1亚群比例显著高于其他髓系肿瘤患者(P=0.027)。
- 84.31%的CMML患者MO1亚群≥94%,符合WHO诊断阈值。
- 不符合MO1或MO3阈值的CMML患者多处于炎症状态。
核心结论
- 外周血单核细胞亚群分析尤其是MO1亚群可较好辅助CMML诊断,但需排除炎症状态。
研究设计与样本
- 回顾性纳入2020年6月1日至2024年12月31日广东省人民医院初诊CMML患者51例(WHO 2022标准),对照组为23例伴外周血单核细胞增多的非CMML髓系肿瘤患者。
- 所有患者行骨髓形态学、活检、染色体、基因检查明确诊断,同时用流式细胞术检测外周血单核细胞亚群MO1、MO2、MO3比例。
主要发现
- CMML患者MO1亚群比例显著高于对照组(P=0.027),MO2和MO3亚群差异无统计学意义(均P>0.05)。
- 43例(84.31%)CMML患者MO1亚群≥94%(WHO阈值),46例(90.20%)MO3亚群≤1.13%(Hudson阈值)。
- 8例未达WHO MO1标准的患者中7例处于炎症状态;5例高于Hudson MO3阈值的患者均处于炎症状态。
- ROC曲线显示本队列MO1亚群临界值为97.55%(AUC=0.661,P=0.027),符合WHO标准。
关键数值与推荐
- WHO诊断标准MO1亚群阈值:MO1%≥94%。
- Hudson团队提出的MO3亚群阈值:MO3%≤1.13%。
- 本队列ROC曲线MO1亚群临界值97.55%(AUC=0.661,P=0.027)。
临床怎么用
- 外周血单核细胞亚群分析可辅助CMML诊断,MO1亚群比例升高支持CMML。
- 解读MO1亚群结果时需排除炎症状态,炎症可导致假阴性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the clinical value of peripheral blood monocyte subset analysis in the diagnosis and treatment of chronic myelomonocytic leukemia (CMML) . Method: We retrospectively enrolled 51 patients newly diagnosed with CMML at Guangdong Provincial People's Hospital between June 1, 2020, and December 31, 2024, according to the WHO 2022 diagnostic criteria. Twenty-three patients with other myeloid neoplasms (excluding CMML) and peripheral monocytosis (absolute count ≥0.5×10(9)/L and percentage ≥10%) were included as the control group. All patients underwent bone marrow aspiration for examinations including bone marrow smears, biopsies, cytogenetics, and gene mutation analysis to establish a definitive diagnosis. Concurrently, flow cytometry was used to determine the proportions of peripheral blood monocyte subsets: classical (MO1, CD14(+)CD16(-)) , intermediate (MO2, CD14(+)CD16(+)) , and non-classical (MO3, CD14(low)CD16(+)) . Differences between the groups were compared, and diagnostic efficacy was evaluated using receiver operating characteristic (ROC) curves. Result: Among the 51 CMML patients, the proportion of the peripheral blood MO1 subset was significantly higher than that in patients with other myeloid neoplasms (P=0.027) , whereas there were no significant differences in the MO2 and MO3 subsets (all P>0.05) . Further analysis revealed that 43 (84.31%) of the CMML patients met the WHO diagnostic threshold for the MO1 subset (≥94%) , while the remaining 8 patients did not; 46 patients (90.20%) had MO3 subset proportions below the threshold proposed by Hudson (≤1.13%) , while the remaining 5 patients were above this threshold. In-depth analysis showed that among the 8 patients who did not meet the WHO criteria, 7 were experiencing inflammation. Similarly, all 5 patients who did not meet the Hudson criteria were in an inflammatory state. Subsequent ROC curve analysis of this cohort identified a cut-off value for the MO1 subset of 97.55% [Area Under the Curve (AUC) =0.661, P=0.027], which aligns with the WHO criteria. Conclusion: Peripheral blood monocyte subset analysis, particularly MO1 subset analysis, can effectively assist in CMML diagnosis, but exclusion of inflammatory conditions is required. 目的: 评估外周血单核细胞亚群在慢性粒-单核细胞白血病(Chronic myelomonocytic leukemia,CMML)诊疗中的应用价值。 方法: 回顾性纳入2020年6月1日至2024年12月31日期间就诊于广东省人民医院初诊CMML患者51例(依据WHO 2022年诊断标准),为研究组;以23例伴有外周血单核细胞增多(绝对值≥0.5×10(9)/L,比值≥10%)的非CMML髓系肿瘤患者为对照组。所有患者均进行骨髓细胞形态学、活检、染色体、基因等检查,明确诊断;同时采用流式细胞术检测外周血单核细胞亚群比例,分析CD14(+)CD16(-)(MO1)、CD14(+)CD16(+)(MO2)及CD14(low)CD16(+)(MO3)各亚群比例,比较组间差异并通过受试者工作特征曲线(ROC曲线)评估诊断效能。 结果: 研究组51例CMML患者中,外周血单核细胞MO1亚群比例明显高于其他髓系肿瘤患者(P=0.027),而MO2、MO3亚群差异均无统计学意义(均P>0.05)。进一步分析发现,CMML患者MO1亚群符合WHO诊断标准MO1亚群阈值(MO1%≥94%)者共43例(84.31%);另8例未达到WHO标准。MO3亚群低于Hudson团队所给出的MO3亚群阈值(MO3%≤1.13%)的患者共46例(90.20%);另5例高于此阈值。进一步分析发现,8例不符合WHO标准的患者中,7例处于炎症状态;5例不符合Hudson标准的患者均处于炎症状态。后续ROC曲线显示本队列中MO1亚群的临界值为97.55%[曲线下面积(AUC)=0.661,P=0.027],符合WHO标准。 结论: 外周血单核细胞亚群分析,尤其是MO1亚群,可较好辅助CMML疾病诊断,但需要排除炎症状态。.
引用
- Wang L, Li MM, Bai JJ, et al. [Analysis of peripheral blood monocyte subsets in chronic myelomonocytic leukemia: a single-center study]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 41339049. doi:10.3760/cma.j.cn121090-20250126-00045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。